Clinical Trials
Open
Phase
Accrual
1%
SWOG Clinical Trial Number
S1900J
A Phase II Study of Amivantamab SC (subcutaneous) in Participants Previously Treated with High MET-Amplification for Stage IV or Recurrent Non-Small-Cell Lung Cancer (Lung-MAP Sub-Study)
Status Notes
S1900J will open to accrual September 27, 2024, effective 3:00 p.m. EST.
Research Committee(s)
LungMAP
Activated
09-27-2024
ClinicalTrials.gov Registry Number
NCT06116682
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Status Notes
S2312 active as of 9/3/2024.
Research Committee(s)
Genitourinary Cancer
Activated
09-03-2024
ClinicalTrials.gov Registry Number
06470243
Open
Phase
Accrual
1%
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Status Notes
S2308 will open to accrual 08/01/2024, effective 3:00 p.m. EST
Research Committee(s)
Lymphoma
Activated
08-01-2024
ClinicalTrials.gov Registry Number
06337318
Open
Phase
SWOG Clinical Trial Number
MYELOMATCH
Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH trials
Research Committee(s)
myeloMATCH
Leukemia
Activated
05-16-2024
ClinicalTrials.gov Registry Number
NCT05564390
Open
Phase
Accrual
1%
SWOG Clinical Trial Number
MM1YA-S01
A Randomized Phase II Study Comparing Cytarabine +Daunurubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH; A myeloMATCH Clinical Trial
Research Committee(s)
myeloMATCH
Leukemia
Activated
05-16-2024
ClinicalTrials.gov Registry Number
NCT05554406
Open
SWOG Clinical Trial Number
S2303
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05-06-2024
ClinicalTrials.gov Registry Number
06203600